comparing cardiovascular and kidney outcomes with tirzepatide vs. glp-1 agonists Bridging the gap between GLP1-receptor outcomes: evidence for the role of | Cardiovascular Diabetology A Comprehensive Review of the
Description
While the contribution of weight loss remains unclear, this study, alongside emerging preclinical data from rodent models, suggests that GLP-1 medicines may offer efficacy in inflammation-driven diseases independent of the amelioration of metabolic dysfunction
Retatrutide is the most advanced triple agonist in clinical research, but other compounds are in earlier-stage development
6-Gingerol mechanistically activated cAMP, PKA, and CREB in pancreatic islets, which are essential to the GLP-1-mediated insulin secretion pathway [211]
J Chin Med Assoc
Shoemaker AH, Chung ST, Fleischman A
